Ayelet B. Shai

HaAliya HaShniya St 8, 3109601
Haifa, HA 31096, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Journal: The oncologist

Published: May 22, 2026

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Journal: The oncologist

Published: May 22, 2026

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.

Journal: Future oncology (London, England)

Published: April 07, 2026

De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.

De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.

Journal: Breast (Edinburgh, Scotland)

Published: March 24, 2026

Response to Verma et al., Letter to the editor.

Response to Verma et al., Letter to the editor.

Journal: Breast (Edinburgh, Scotland)

Published: January 23, 2026

Response to Wein et al.: Endocrine time zero, endocrine effect? Re-reading OFS+AI after residual disease.

Response to Wein et al.: Endocrine time zero, endocrine effect? Re-reading OFS+AI after residual disease.

Journal: Breast (Edinburgh, Scotland)

Published: January 22, 2026

Disability Bias in Patient Prioritization: How Patients' Mobility Impairments Influences Prioritization to Mechanical Ventilation.

Disability Bias in Patient Prioritization: How Patients' Mobility Impairments Influences Prioritization to Mechanical Ventilation.

Journal: Journal of general internal medicine

Published: September 12, 2025

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 05, 2025

Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy.

Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy.

Journal: Breast (Edinburgh, Scotland)

Published: June 03, 2025

Chronic cannabis use in breast cancer survivors: A questionnaire study of Israeli patients.

Chronic cannabis use in breast cancer survivors: A questionnaire study of Israeli patients.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: May 06, 2025

Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.

Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 18, 2024

Characterization of the tumor microbiome of brain metastases and glioblastoma reveals tumor-type-specific and location-specific microbial signatures.

Characterization of the tumor microbiome of brain metastases and glioblastoma reveals tumor-type-specific and location-specific microbial signatures.

Journal: Nature cancer

Published: November 29, 2024

Showing 1-12 of 47

Last Updated: 09/26/2026